We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
GMAB.CO

Price
1251.50
Stock movement down
-33.50 (-2.61%)
Company name
Genmab A/S
Exchange
(CO
,
Currency
DKK
)
Sector
Healthcare >
Biotechnology
Market cap
79.50B
Ent value
80.90B
Price/Sales
4.02
Price/Book
2.49
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
17.14
Forward P/E
13.30
PEG
-
EPS growth
22.93%
1 year return
-39.95%
3 year return
-20.39%
5 year return
-1.66%
10 year return
8.76%
Last updated: 2025-04-05

DIVIDENDS

GMAB.CO does not pay dividends or no data was received

VALUATION

Valuation Ratios

Valuation Ratios data
Trailing P/E17.14
Price to OCF11.81
Price to FCF12.12
Price to EBITDA20.56
EV to EBITDA20.92

Valuation (Sales/Book Value)

Valuation (Sales/Book Value) data
Price to Sales4.02
Price to Book2.49
EV to Sales4.09

FINANCIALS

Per share

Per share data
Current share count63.52M
EPS (TTM)72.59
FCF per share (TTM)102.66

Income statement

Income statement data
Revenue (TTM)19.76B
Gross profit (TTM)18.99B
Operating income (TTM)6.21B
Net income (TTM)4.64B
EPS (TTM)72.59
EPS (1y forward)94.12

Margins

Margins data
Gross margin (TTM)96.08%
Operating margin (TTM)31.44%
Profit margin (TTM)23.47%

Balance Sheet

Please create a free account or log in to access this chart
Balance Sheet data
Cash6.34B
Net receivables6.31B
Total current assets23.70B
Goodwill2.41B
Intangible assets11.50B
Property, plant and equipment0.00
Total assets39.66B
Accounts payable0.00
Short/Current long term debt987.00M
Total current liabilities4.58B
Total liabilities7.74B
Shareholder's equity31.92B
Net tangible assets0.00

Cash flow

Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)6.73B
Capital expenditures (TTM)170.00M
Free cash flow (TTM)6.56B
Dividends paid (TTM)0.00

Financial returns

Please create a free account or log in to access this chart
Financial returns data
Return on Equity14.53%
Return on Assets11.70%
Return on Invested Capital14.49%
Cash Return on Invested Capital20.49%

STOCK INFORMATION

Stock chart

Stock price data
Open1285.00
Daily high1306.00
Daily low1247.50
Daily Volume194K
All-time high3295.00
1y analyst estimate2340.18
Beta0.86
EPS (TTM)72.59
Dividend per share-
Ex-div date-
Next earnings date30 Apr 2025

Downside potential

Downside potential data
GMAB.COS&P500
Current price drop from All-time high-62.02%-17.56%
Highest price drop-94.14%-56.47%
Date of highest drop23 Nov 20119 Mar 2009
Avg drop from high-39.40%-11.07%
Avg time to new high37 days12 days
Max time to new high1915 days1805 days
COMPANY DETAILS
GMAB.CO (Genmab A/S) company logo
Marketcap
79.50B
Marketcap category
Large-cap
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Employees
2635
Website
https://www.genmab.com
Investor relations
-
SEC filings
GMAB.CO SEC filings
CEO
Country
Denmark
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
UNDERSTAND THE BUSINESS
COMPANY NEWS
All newsPress releases
No items found
Disclaimer
Skyfall Technology OÜ assumes no responsibility or liability for any errors or omissions in the content of this site. The information contained in this site is provided on an “as is” basis with no guarantees of completeness, accuracy, usefulness or timeliness. Please also note, that any action you take upon the information provided on this website is strictly at your own risk. This website is intended to be used and must be used for informational purposes only and you should take independent financial advice from a professional and independently research and verify everything you see on the site.
Menu
HomePortfolio ManagementCompany ScreenerGreen InvestmentExchangesContact Us
Language
ENHUNOSVDAFIESDENLFRITPTPLCSSKROELTRRUAF
© 2024 Skyfall Technology OÜ All Rights Reserved